Cytotoxicity and intracellular biotransformation of N-benzyladriamycin- 14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 58-66

  Lothstein, Leonard ^a   Rodrigues, Patrick J ^a   Sweatman, Trevor W ^a   Israel, Mervyn ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

AD 198; Anthracyclines; Doxorubicin; Drug resistance; Topoisomerase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; N BENZYLDOXORUBICIN 14 VALERATE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CYTOTOXICITY; DRUG STABILITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; DOXORUBICIN; MACROPHAGES; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031936753     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00007     Document Type: Article

References (35)

1. Sweatman TW, Israel M, Koseki Y, et al. Cytotoxicity and cellular pharmacology of N-benzyladriamycin-14-valerate in mechanistically different multidrug-resistant human leukemic cells. J Cell Pharmacol 1990; 1: 95-102.
2. Israel M, Seshadri R, Koseki, Y, et al. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev 1987; 14: 163-7.
3. Lothstein L, Sweatman TW, Dockter ME, et al. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res 1992; 52: 3409-17.
4. Lothstein L, Koseki Y, Sweatman TW. P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198). Anti-Cancer Drugs 1994; 5: 623-33.
5. Lothstein L, Wright H, Sweatman TW, et al. N-Benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modifications with intracellular accumulation and distribution in multidrug resistant cells. Oncology Res 1992; 4: 341-34.
6. Lothstein L, Sweatman W, Dockter ME, et al. Differential distribution of N-benzyladriamycin-14-valerate (AD 198) and N-benzyladriamycin (AD 288) in multidrug-resistant mouse J774.2 cells. Proc Am Ass Cancer Res 1991; 32: 356.
7. Sweatman TW, Seshadri R, Israel M. Metabolism and elimination of N-benzyladriamycin-14-valerate (AD 198) in the rat. Proc Am Ass Cancer Res 1989; 30: 532.
8. Israel M Seshadri R. US Patent no. 4,610,977, 1989.
9. Arcamone F, Franceschi G, Minghetti A, et al. Synthesis and biological evaluation of some 14-O-acyl derivatives of adriamycin. J Med Chem 1974; 17: 335-7.
10. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
11. Israel M, Sweatman TW, Seshadri R, et al. Comparative uptake and retention of Adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol 1989; 25: 177-83.
12. Danks MK, Schmidt CA, Cirtain MC, et al. Altered catalytic activity of and DNA cleavage by DNA topoisomerase 11 from human leukemic cells selected for resistance to VM-26. Biochemistry 1988; 27: 8861-9.
13. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
14. Sahai BM, Kaplan GK. A quantitative decatenation assay for type II topoisomerases. Anal Biochem 1986; 156: 364-79.
15. Burke TG, Israel M, Seshadri R, et al. A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles. Biochim Biophys Acta 1989; 982: 123-30.
16. Bodley A, Liu LF, Israel M, et al. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 1989; 49: 5969-78.
17. Israel M, Seshadri R, Koseki Y, et al. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev 1987; 14: 163-7.
18. Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther 1993; 60: 215-34.
19. Priebe W. Mechanism of action-governed design of anthracycline antibiotics: a turn-off/turn-on approach. Current Drug Design 1995; 1: 73-96.
20. Sweatman TW, Seshadri R, Israel M. Selective retention of N-Benzyladriamycin-14-valerate (AD 198) in the rat lung following intravenous drug administration. Proc Am Ass Cancer Res 1992; 33: 520.
21. Lothstein L, Hosey LM, Sweatman TW, et al. N-benzyladriamycin-14-valerate-resistant cells exhibit cross-resistance to other anthracycline analogs that circumvent multidrug resistance. Oncol Res. 1993; 5: 229-34.
22. Seshadri R, Idriss JM, Israel M. Adriamycin analogues. Preparation and biological evaluation of some thio ester analogues of adriamycin and N-(trifluoroacetyl)adriamycin-14-valerate. J Med Chem 1986; 129: 1269-73.
23. Seshadri R, Israel M, Pegg WJ. Adriamycin analogues. Preparation and biological evaluation of some novel 14-thioadriamycins. J Med Chem 1983; 26: 11-5.
24. Lampidis TJ, Castello C, Del Giglio A, et al. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochem Pharmacol 1989; 38: 4267-71.
25. Tang-Wai DF, Brossi A, Arnold LD, et al. The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry 1993; 32: 6470-6.
26. Priebe W, Van NT, Burke TG, et al. Removal of the basic center from doxonibicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs 1993; 4: 37-48.
27. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988, 33: 454-62.
28. 3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer 1993; 67: 226-31.
29. Ganapathi R, Grabowski D, Sweatman TW, et al. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterization of cross-resistance in vitro and in vivo. Br J Cancer 1989; 60: 819-26.
30. Lampidis TJ, Kolonias D, Podona, T, et al. Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. Biochemistry 1997; 36: 2679-85.
31. Capranico G, Butelli E, Zunino F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 1995; 55: 312-7.
32. Jensen PB, Sorensen BS, Sehested M, et al. Different modes of anthracycline interaction with topoisomerase II. Biochem Pharmacol 45: 2025-35.
33. Capranico G, Zunino F, Kohn KW, et al. Sequence-selective topoisomerase 11 inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and toxicity. Biochemistry 1990; 29: 562-9.
34. Solary E, Ling Y-H, Perez-Soler R, et al. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int J Cancer 1994; 58: 85-94.
35. Lothstein L, Sweatman TW, Priebe W. Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance. Bioorg Med Chem 1995; 5: 1807-12.